Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IDEXX LaboratoriesFRA:IX1 -0.90%98 EV-to-EBIT is 31.82 as of Jul. 27, 2026, which is 23% below its 10-year median of 41.43. GuruFocus rates FRA:IX1 with a GF Score™ of 98/100 and a GF Value™ of €550.96 (Modestly Undervalued). Among 104 Medical Diagnostics & Research companies, IDEXX Laboratories ranks worse than 68.27% on this metric.
The historical rank and industry rank for IDEXX Laboratories's EV-to-EBIT or its related term are showing as below:
FRA:IX1'
s EV-to-EBIT Range Over the Past 10 Years
Min: 28.49 Med: 41.43 Max: 70.45
Current: 31.13
During the past 13 years, the highest EV-to-EBIT of IDEXX Laboratories was 70.45. The lowest was 28.49. And the median was 41.43.
FRA:IX1's EV-to-EBIT is ranked worse than 68.27% of 104
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.47
vs FRA:IX1: 31.13
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
IDEXX Laboratories's Enterprise Value for the quarter that ended in Mar. 2026 was €39,452 Mil.
IDEXX Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,211 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEXX Laboratories EV-to-EBIT Related Terms
IDEXX Laboratories EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for IDEXX Laboratories's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, IDEXX Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's EV-to-EBIT falls into.
IDEXX Laboratories's current Enterprise Value is €38,538 Mil.
IDEXX Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,211 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEXX Laboratories (FRA:IX1) has a EV-to-EBIT of 31.82 as of Jul. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on IDEXX Laboratories and its competitors. This is 23% below median its historical median of 41.43. Over the past decade, IDEXX Laboratories' EV-to-EBIT has ranged from 28.49 to 70.45. According to the industry distribution chart, IDEXX Laboratories ranks #71 out of 104 companies in the Medical Diagnostics & Research industry, placing it in the top 68.3%.
Is IDEXX Laboratories' EV-to-EBIT too high?
IDEXX Laboratories' current EV-to-EBIT of 31.82 is 23% below median its 10-year median of 41.43. Over the past 10 years, this metric has ranged from a low of 28.49 to a high of 70.45. The Medical Diagnostics & Research industry median EV-to-EBIT is 22.47. IDEXX Laboratories' value of 31.82 is 41.6% above this industry median. Based on the distribution chart, IDEXX Laboratories ranks #71 out of 104 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, IDEXX Laboratories has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' EV-to-EBIT compare to A and NTRA?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #71 out of 104 companies for EV-to-EBIT. This places IDEXX Laboratories in the lower half of its industry. The industry median EV-to-EBIT is 22.47. IDEXX Laboratories' value of 31.82 is 41.6% above this benchmark. Historically, IDEXX Laboratories' own EV-to-EBIT has ranged from 28.49 to 70.45 over the past decade. While the company's 10-year median is 41.43 vs. the industry median of 22.47, IDEXX Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 22.47, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDEXX Laboratories's current EV-to-EBIT of 31.82 is 41.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on IDEXX Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 22.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEXX Laboratories's current EV-to-EBIT is 31.82, which is 23% below median its own 10-year median of 41.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €550.96, compared to a current price of €472.20 — trading 14.3% below its estimated fair value. The current EV-to-EBIT is 31.82, which is 23% below median its 10-year median of 41.43 and 41.6% above the Medical Diagnostics & Research industry median of 22.47. IDEXX Laboratories' overall GF Score™ is 98/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current EV-to-EBIT is 31.82 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €472.20 is trading 14.3% below its estimated GF Value™ of €550.96.
GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.
Key valuation signals for FRA:IX1:
EV-to-EBIT: 31.82 (23% below median its 10-year median of 41.43)
GF Value™: €550.96 vs. price of €472.20 (14.3% below fair value)
Industry Position: 41.6% above the Medical Diagnostics & Research median (#71 of 104)
No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
98GF Score
Get the complete analysis for FRA:IX1
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IX1 has been successfully added to your 
